# US 2025/0082706 A1 · Fermented ginseng radix et rhizoma extract, product for alleviating non-alcoholic fatty liver disease, method for promoting increase of content of aglycone flavonoids and/or short-chain fatty acids in ginseng radix et rhizoma extract, and method for promoting efficacy of ginseng radix et rhizoma extract in alleviating non-alcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082706 A1
- Document ID: US20250082706A1
- Status: Published application
- Kind: A1
- Application number: 18/746,083
- Filed: 2024-06-18
- Published: 2025-03-13
- Earliest claimed: 2023-09-13
- Assignees: Infinitus (China) Company Ltd.
- Applicants: Infinitus (China) Company Ltd.
- Inventors: Cencen LIU; Shumao CUI; Hongwei ZHAO; Jian TANG; Fei LIU
- Web page: https://patentgrep.com/patent/US20250082706A1

## CPC

- A61K 36/258: Panax (ginseng)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61K 2236/19: involving fermentation using yeast, bacteria or both; enzymatic treatment
- A61K 2236/53: Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention discloses use of Bifidobacterium animalis subsp.lactis in promoting efficacy exertion of a Ginseng Radix Et Rhizoma extract in alleviating liver injuries. According to the present invention, Bifidobacterium animalis subsp.lactis CCFM1274 may grow in a fermentation base rich in a Ginseng Radix Et Rhizoma extract, and a fermentation broth of the Ginseng Radix Et Rhizoma extract fermented with this strain can increase the content of active substances such as aglycone flavonoids and short-chain fatty acids, promote the efficacy exertion of the Ginseng Radix Et Rhizoma extract, including improving the ability of the Ginseng Radix Et Rhizoma extract to alleviate a non-alcoholic liver injury, and reduce the fat accumulation in liver cells. This strain and the Ginseng Radix Et Rhizoma extract may be used to prepare a product for promoting the efficacy of alleviating the non-alcoholic liver injury.

## Claims

### Claim 1

A fermented Ginseng Radix Et Rhizoma extract, obtained by subjecting a Ginseng Radix Et Rhizoma extract to fermentation with Bifidobacterium animalis subsp.lactis CCFM1274, wherein the Bifidobacterium animalis subsp.lactis CCFM1274 is preserved in Guangdong Microbial Collection Center on Sep. 15, 2022, with a preservation number of GDMCC No. 62798.

### Claim 2 (depends on 1)

The fermented Ginseng Radix Et Rhizoma extract according to claim 1, wherein the fermented Ginseng Radix Et Rhizoma extract is capable of promoting an efficacy of alleviating a non-alcoholic fatty liver disease.

### Claim 3 (depends on 1)

The fermented Ginseng Radix Et Rhizoma extract according to claim 1, wherein the fermented Ginseng Radix Et Rhizoma extract is capable of increasing a content of aglycone flavonoids and/or short-chain fatty acids.

### Claim 4 (depends on 1)

The fermented Ginseng Radix Et Rhizoma extract according to claim 1, comprising at least one of the following functions:
(1) improving a proliferation activity of liver cells;
(2) reducing a number of red lipid droplets in the liver cells;
(3) increasing contents of aspartate aminotransferase and alanine aminotransferase in the liver cells;
(4) increasing a TG clearance rate; and
(5) inhibiting lipid accumulation in the liver cells.

### Claim 5 (depends on 1)

A product for alleviating non-alcoholic fatty liver disease, comprising the fermented Ginseng Radix Et Rhizoma extract according to claim 1.

### Claim 6 (depends on 5)

The product according to claim 5, wherein the product is food, drugs or health products.

### Claim 7 (depends on 5)

The product according to claim 5, comprising at least one of the following functions:
(1) improving a proliferation activity of liver cells;
(2) reducing a number of red lipid droplets in the liver cells;
(3) increasing contents of aspartate aminotransferase and alanine aminotransferase in the liver cells;
(4) increasing a TG clearance rate; and
(5) inhibiting lipid accumulation in the liver cells.

### Claim 8 (depends on 1)

A method for promoting increase of content of aglycone flavonoids and/or short-chain fatty acids in Ginseng Radix Et Rhizoma extract, comprising adding the Bifidobacterium animalis subsp.lactis CCFM1274 according to claim 1 to a system containing the Ginseng Radix Et Rhizoma extract for fermentation, wherein the Ginseng Radix Et Rhizoma extract fermented has a higher content of aglycone flavonoids and/or short-chain fatty acids than that in the Ginseng Radix Et Rhizoma extract before fermentation.

### Claim 9 (depends on 1)

A method for promoting efficacy of Ginseng Radix Et Rhizoma extract in alleviating non-alcoholic fatty liver disease, comprising adding the Bifidobacterium animalis subsp.lactis CCFM1274 according to claim 1 to a system containing the Ginseng Radix Et Rhizoma extract for fermentation, wherein the Ginseng Radix Et Rhizoma extract fermented has better efficacy in alleviating the non-alcoholic fatty liver disease than that of the Ginseng Radix Et Rhizoma extract before fermentation.
